Subsidiaries
Company introduction
Brand history
Teresting story


Affiliated to Shanghai Pharma, New Asiatic Pharmaceutical is a large-scale pharmaceutical enterprise set up through strategic reorganization of the New Asiatic Pharmaceuticals, Pioneer Pharmaceutical and No. 4 Pharmaceutical Plant, which were the three backbone antibiotic manufacturing enterprises affiliated to Shanghai Pharma.

One of the biggest anti-biotic manufacturers in China, the Company boasts to run an integrated industrial chain that covers the R&D, raw materials, preparations and sales. The Company owns three major brands, including “Three-Flower”, “Yazi” and “Four-Star”, with its product lines covering the anti-infection drugs of all existing categories. The Company is recognized as one of the domestic anti-biotics manufacturer with the most comprehensive, diversified, and characteristic product lines.The Company is ranked among the top few in the domestic market by virtue of such key products as Ceftriaxone, Cefotaxime, Cefoperazone, Cefotiam, Cefazolin, etc.

Implementing the natural mission of “caring about life and creating health”, the Company always adheres to the guidelines to be an enterprise assuming social responsibilities and advocates applying medicine according to indications by making rational use of antibiotics and opposing any abuse of the same. As a hi-tech enterprise in Shanghai, Xinya Pharmaceuticals is dedicated to pursuing constant innovations while cherishing the heritage and adheres to such operational conceptions termed as “Quality Creates Values and Innovations Lead to Future Success”, and sticks to creating values with outstanding brands and qualities for the benefit of the society, shareholders, customers, enterprise as well as employees, and to seeking extensive innovations in mechanisms, technologies, management, marketing operations, talent operations and customer services. By relentless efforts to inherit, innovate and to perfect qualities, the Company also takes the initiatives to develop the specialized dosage forms that focus on injections, while striving to explore the oncologic and cardiovascular areas, with steps taken forward in attainment of the great cause of a Chinese pharmaceutical giant player.

In 1866, Kefa, a German pharmacist, opened Kefa Pharmacy at the site, which is now No. 136 of the East Nanjing Road.
In 1909, Kefa set up the Kefa Pharmaceutical Plant at Huade Road in Shanghai (currently No. 1568 Changyang Road) and mainly engaged in the production of Wogulin Eye Drops, BaisongZhikeTangjiangand Kefa Heatstroke Liquid Medicine.
In 1926, Shanghai New AsiaticPharmaceutical Plant was set up, which was one of the earliest national pharmaceutical enterprises ever established in China. The“Xinya” brandas demonstrated by the logo of “a Chinese character 亚 within a five-pointed star” has been noted for the remarkable popularity both at home and abroad. The first product ever marketed bearing the “亚” brand trademark was the “Renshoushui” or the “Life Fluid” produced in 1926.
In 1931, the “亚” brand pharmaceutical products pioneered in China with the establishment of a quality monitoring and assurance system in contribution to the development of the Chinese national medicine.
In 1950, the first penicillin lab was built up in China and began to be engaged in the development and production of antibiotics. That was the first State-owned enterprise specifically engaged in the manufacturing of antibiotics and was later on referred to as the cradle of the Chinese antibiotics.
In 1963, the first semi-synthetic antibiotic was successfully developed.
In 1971, the first semi-synthetic cephalosporin(Xianfeng No. 1) was put into production.
In 1982, as the first Chinese enterprise to go through the examinations by the US FDA, pioneered in passing through the FDA examinations and passed for 8 consecutive reviewing examinations thereafter with the products marketed in over 40 countries and regions in Europe, North America, Asia, Africa and Australia.
From 1991 through 2004 awarded for 7 consecutive years the honorary title of the Model Unit of Spiritual Civilization in Shanghai.
In 2002, one of the Top 60 pharmaceutical enterprises in China.
In 2002, appraised to be one of the outstanding enterprises in the contending-and-striving-for-excellence campaign for construction of a new industrial highland as launched in the City of Shanghai.
In 2002, awarded the honorary title of the Model Unit of Shanghai by the Municipal People’s Government of Shanghai.
In 2002, the “Xinya” brand Ceftriaxone Sodium for Injection, Sodium Fructose Diphosphate For Injection, Cefazolin Sodium for Injection, and the Green Ointment were listed in the Top 100 famous-brand products of Shanghai through appraisals by Shanghai FamousBrand Recommendation Committee.
In 2002, awarded the honorary title of the Hi-Tech Enterprise of Shanghai.
In 2003, the Ceftriaxone Sodium for Injection, Sodium Fructose DiphosphateFor Injection, Compound Ketoconazole Cream were appraised to be the famous-brand products of Shanghai.
In 2004, awarded the honorary title of one of the Top 500 Enterprises in terms of the sales revenues among the industrial enterprises in Shanghai.
In January 2004, awarded the honorary title of “Establishment of National Aspirations and Creation of World-Famous Brand” through appraisals by Shanghai Famous Brand Recommendation Committee.
In 2005, awarded the honorary title of the “Recognized Hi-Tech Enterprise” through appraisals by the Science & Technology Committee of Shanghai.
In 2011, awarded the honorary certificate of the Hi-Tech Enterprise of Shanghai.
In 2012, appraised to be an “Outstanding Hi-Tech Enterprise of Shanghai”.
In 2010 and 2013, awarded consecutively the honorary title of the “Renowned Trademark of Shanghai”.

 

How Penicillin came into being in China

In 1948, an American, who bore a title of the so-called “expert”, came to China and said he would like to “assist” China in the construction of a penicillin plant. The KMT government entertained this “allied friend” as a distinguished guest. During the negotiations this so-called expert protruded three fingers for the three conditions for the proposed plant: first, the production facilities should be ordered from the US; second, the pharmaceutical technicians should be dispatched from the US and third 50% of the profit as generated following the commercial operation of the plant should go to the US.
Ever since the founding of New China, “we cannot rely on the Yankees,” was the idea agreed to even without prior consultation by and between the military representative Shi Yumin and the antibiotic expert Tong Cun and both of them worked together on the major program on the preparation for construction of the antibiotic plants in New China. Mayor Chen Yi approved in person the plant construction projection and the East China Administration appointed 9 comrades, including Shi Yumin, Tong Cun, Song Guobin, Ma Shijie, GeFuzhen, Huang Fengqiu, QiuBeishan, Chen Haoxian and Yuan Shaoting, to be the members of the Plant Set-up Committee. Since then, under the leadership of the Communist Party of China, the antibiotic young people of New China followed Dr. Tong Cun and dedicated themselves to the establishment of the “Penicillin Lab” and the drawing of a wonderful blueprint of the antibiotic undertakings in the New China.
In April 1951, the trial production of the Penicillin Sylvite was successfully accomplished. Hence the commencement of the antibiotic industry in China. With drums beating and cymbals clashing, Dr. Tong Cun tightly held the hands of a leader from the East China Administration and choked with sobs, “we have eventually removed the shame of being unable to produce penicillin in China,” his eyes filled with tears.
Starting from the early 1990s, the EC launched the anti-dumping investigations against China on theDihydrostreptomycin, while No. 4 Pharmaceutical Plant of Shanghai and Sichuan Changzheng Pharmaceutical Plant took the initiatives to counteract and after the “lawsuits” that prolonged for 5 years, we eventually won the proceedings. That is noted to be the first case of anti-dump counteractions, in which the Chinese pharmaceutical industry hasever been involved.

The subject of concern
Produced By 大汉网络 大汉版通发布系统